Tumor cells frequently overexpress PD-L1, allowing for the immunoediting of cancer cells by binding PD-L1 on tumor surfaces to PD-1 on T cells, thus inhibiting their anti-tumor activity. This evidence concerns the gene CD274 and neoplasm.